PBI-Gordon Companies Acquires TriviumVet

Gryphon Investors Acquires Vetnique Labs

April 20, 2023

Consumer Products

Gryphon Investors, a San Francisco-based private equity firm, has acquired Vetnique Labs, a Naperville, Illinois-based pet health and wellness company. Gryphon will partner with founder and CEO James Bascharon (who will remain in role and retain a significant stake) to expand Vetnique’s product portfolio and geographic reach; financial terms were not disclosed.

Shionogi Acquires Tetra Therapeutics

May 26, 2020

Biotechnology

Shionogi & Co., Ltd. agreed to acquire clinical-stage biopharmaceutical company Tetra Therapeutics, giving Shionogi global rights to Tetra's portfolio including BPN14770. The deal, announced May 26, 2020, is valued at up to $500 million in milestone and contingent payments.

WCG Acquires Trifecta Clinical

December 3, 2020

Healthcare Services

WCG has acquired Trifecta Clinical, a provider of technology-enabled clinical trial site communications and training solutions including the InvestigatorSpace platform. The deal brings Trifecta's investigator training, safety letter distribution and document-exchange capabilities into WCG's suite of clinical research services while Trifecta retains its leadership and offices in Los Angeles and other locations.

Kohlberg & Company Recapitalizes Trinity Life Sciences

November 30, 2021

Healthcare Services

Kohlberg & Company will recapitalize Trinity Life Sciences, replacing Parthenon Capital as the company’s capital partner. The transaction provides Trinity with new growth capital to support global expansion, technology and data-driven capability investments while Trinity’s management team, led by CEO David Fitzhenry, will remain in place.

Convatec Group Acquires Triad Life Sciences

January 28, 2022

Medical Devices

Convatec Group Plc has signed a definitive agreement to acquire Triad Life Sciences Inc, a Memphis-based developer and manufacturer of porcine placenta‑derived extracellular matrix products for advanced wound care. The deal, expected to close in Q1 2022 subject to regulatory approvals, values Triad at an initial $125 million with up to $275 million additional contingent/earnout payments tied to milestones and performance.

PAI Pharma Acquires Nivagen Pharmaceuticals

January 8, 2026

Pharmaceuticals

PAI Pharma, an Olympus Partners portfolio company, has acquired Nivagen Pharmaceuticals to add a newly built aseptic sterile-injectable manufacturing facility in Sacramento, California and a pipeline of more than 20 ready-to-use (RTU) injectable products. The add-on expands PAI's sterile injectable capabilities alongside its oral liquid franchise to better serve hospitals and health systems and strengthen U.S. pharmaceutical supply-chain resilience; financial terms were not disclosed.